04/14/2026
Philippines FDA Tightens Rules for Post-Approval Changes in Medical Devices (2025)
Post-approval changes just became clearer in the Philippines.
The FDA Philippines (CDRRHR) has issued a draft circular introducing a new framework for managing variations to medical devices, IVDs, and health-related devices.
This update aligns with Republic Act No. 9711 and aims to bring more structure, predictability, and a risk-based approach to regulatory decision-making.
The key change is a clearer classification of variations into major, minor, and notification-based updates, including specific rules for Medical Device Software.
It also formalizes a risk-based system where the regulatory pathway depends on the impact of the change on safety, performance, and quality. Low-risk updates can follow simplified processes, while higher-risk changes require full review.
The FDA further strengthens guidance on submission requirements, review timelines, fees, deficiency handling, and lifecycle management, including labeling, renewals, and post-market obligations.
Software updates receive special attention, reflecting the growing role of digital health in medical devices.
Overall, this update improves clarity, consistency, and efficiency in how post-approval changes are handled in the Philippines.
For manufacturers, this means faster pathways for low-risk changes and stronger expectations for compliance and documentation.
At Arazy Group, we help MedTech companies navigate global regulatory complexity and accelerate market access with confidence.
Need support with regulatory strategy or market access in the Philippines?
Let’s connect: https://hubs.ly/Q04b_DdQ0
Source: https://hubs.ly/Q04b_Cx20
